Ipinzan (Metformin Hydrochloride, Vildagliptin)

Ipinzan, a fixed‑dose combination of metformin and vildagliptin, is used in the management of type 2 diabetes mellitus and related therapeutic pathways.

• Type 2 diabetes mellitus: improves overall glycaemic control by lowering fasting and post‑prandial glucose levels.
• Inadequate control on metformin monotherapy: adds DPP‑4 inhibition to achieve additional HbA1c reduction.
• Early-stage type 2 diabetes in adults: assists in reaching target blood glucose when lifestyle measures alone are insufficient.

• Metformin Hydrochloride reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, thereby decreasing basal glucose production. Vildagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The combined effect increases glucose‑dependent insulin secretion and suppresses glucagon release, resulting in improved post‑prandial and fasting glycaemic control. Together, these mechanisms contribute to lower HbA1c levels over time.

Ipinzan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Gastrointestinal upset (nausea, abdominal discomfort, diarrhea).
• Headache.
• Upper respiratory tract infection.

Serious or Rare Side Effects

• Lactic acidosis (rare but potentially fatal).
• Severe hypoglycemia, especially when combined with insulin or sulfonylureas.
• Pancreatitis.
• Anaphylactic reactions.

When prescribing Ipinzan, several precautions should be observed to ensure patient safety.

• Renal function assessment: evaluate creatinine clearance before initiation and periodically during therapy.
• Hepatic function monitoring: avoid use in patients with significant liver disease due to risk of lactic acidosis.
• Cardiovascular status: use cautiously in patients with congestive heart failure or unstable cardiac conditions.
• Elderly patients: start at lower dose and monitor for accumulation and adverse effects.
• Drug interactions: review concomitant medications that may affect renal clearance or increase hypoglycemia risk.
• Store at room temperature: keep tablets in the original container, protect from moisture and light.

Ipinzan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation.
• Insulin or sulfonylureas: combined use can cause severe hypoglycemia.
• Cimetidine: can raise metformin plasma concentrations, increasing risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen, naproxen): may impair renal function, affecting metformin clearance.
• Diuretics (e.g., thiazides, loop diuretics): can reduce renal perfusion and increase metformin levels.
• ACE inhibitors or ARBs: monitor renal function and electrolytes when used together.